Article PDF
References
Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on localregional disease in women with operable breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493
Ellis M, Ma C (2007) Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 105:33–43
Smith IE, Dowsett M, Ebbs SR et al; IMPACT Trialists Group (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23: 5108–5116
Cataliotti L, Buzdar AU, Noguchi S et al (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer 106:2095–2103
Llombart-Cussac A, Guerrero A, Galán A et al (2012) Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. Clin Transl Oncol 14:125–131
Dixon JM, Renshaw L, Macaskill EJ et al (2009) Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat 113:145–151
Bedard PL, Cardoso F (2011) Can some patients avoid adjuvant chemotherapy for early-stage breast cancer? Nat Rev Clin Oncol 8:272–279
Colleoni M, Bagnardi V, Rotmensz N et al (2009) Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 116:359–369
Dowsett M, Smith IE, Ebbs SR et al; IMPACT Trialists Group (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167–170
Ellis MJ, Tao Y, Luo J et al (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100:1380–1388
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cardoso, F. Neoadjuvant endocrine therapy: for whom, for how long?. Clin Transl Oncol 14, 81–82 (2012). https://doi.org/10.1007/s12094-012-0765-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-012-0765-7